NeOnc Technologies Holdings Yönetim

Yönetim kriter kontrolleri 0/4

NeOnc Technologies Holdings CEO'su Amir Heshmatpour, Apr2025 tarihinde atandı, in görev süresi 1.42 yıldır. şirketin hisselerinin 29.61% doğrudan sahiptir ve bu hisselerin değeri $ 27.82M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 1.5 yıldır.

Anahtar bilgiler

Amir Heshmatpour

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.4yrs
CEO sahipliği	29.6%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Oct 09

NeOnc Technologies: From Survival Mode To Expansion Mode

Summary NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials. NTHI's financials are challenging, with no revenue, rising R&D expenses, and a significant cash burn, but a $50M Quazar partnership is set to transform its outlook. The Quazar deal will provide crucial funding, pay off debts, and enable NTHI to accelerate clinical development and expansion in the MENA region. Read the full article on Seeking Alpha

CEO

Amir Heshmatpour (59 yo)

1.4yrs

Görev süresi

Mr. Amir Farrokh Heshmatpour is the Founder of AFH Holding & Advisory LLC and has been its Managing Director since July 2003. Mr. Heshmatpour has been Executive Chairman and Secretary at Neonc Technologies...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Amir Heshmatpour	President	1.4yrs	Veri yok	29.61% $ 27.8m
Thomas Chen	Founder	3.3yrs	US$212.00k	14.18% $ 13.3m
Keithly Garnett	Chief Financial Officer	3.4yrs	US$179.00k	1.45% $ 1.4m
Josh Neman-Ebrahim	Chief Clinical Officer	2.3yrs	US$165.00k	0.84% $ 786.3k
David Choi	Chief Accounting Officer	less than a year	Veri yok	0.45% $ 422.9k

1.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: NTHI 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Amir Heshmatpour	President	3.7yrs	Veri yok	29.61% $ 27.8m
Thomas Chen	Founder	3.3yrs	US$212.00k	14.18% $ 13.3m
Jimmy Delshad	Independent Director	1.5yrs	US$443.00k	0.22% $ 208.9k
Henry Friedman	Chair of the Scientific Advisory Board	1yr	Veri yok	Veri yok
Victoria Medvec	Independent Director	1.5yrs	US$443.00k	0.20% $ 189.6k
David Ashley	Member of Scientific Advisory Board	1yr	Veri yok	Veri yok
Nasim Shomali	Director	less than a year	Veri yok	0.20% $ 189.6k
Bader Al Monawer	Independent Director	1.5yrs	US$443.00k	0.20% $ 189.6k
Axel Schonthal	Scientific Advisory Board Member	no data	Veri yok	Veri yok
Steven Giannotta	Scientific Advisory Board Member & Independent Director	1.5yrs	US$443.00k	0.20% $ 189.6k
Alexandra Miller	Member of the Scientific Advisory Board	less than a year	Veri yok	Veri yok
Nahyan bin Zayed Al Nahyan	Executive Chairman of NuroMENA Holdings Ltd.	less than a year	Veri yok	Veri yok

1.5yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NTHI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/15 13:48
Gün Sonu Hisse Fiyatı	2026/09/15 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

NeOnc Technologies Holdings, Inc. 4 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Matthew Venezia	Alliance Global Partners
Thomas Shrader	BTIG
Jason McCarthy	Maxim Group

NeOnc Technologies Holdings Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

President recently bought US$136k worth of stock

Neonc Technologies Holdings, Inc. Announces Board and Committee Changes, Effective August 18, 2026

Founder recently bought US$140k worth of stock

Neonc Technologies Holdings, Inc. Announces Appointment of Nasim Shomali to Board of Directors, Effective July 1, 2026

NeOnc Technologies Holdings, Inc. Announces Board and Committee Changes

NeOnc Technologies Holdings, Inc., Annual General Meeting, Aug 14, 2026

Recent updates

President recently bought US$136k worth of stock

Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer

NeOnc Technologies Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $15.000006 million.

Neonc Technologies Holdings, Inc. Announces Board and Committee Changes, Effective August 18, 2026

Founder recently bought US$140k worth of stock

Neonc Technologies Holdings Reports Phase 2A Clinical Update for Intranasal Neo100 in Recurrent Idh1-Mutant High-Grade Glioma

New major risk - Financial position

Neonc Technologies Announces Topline Phase 2A Data Readout for Neo100 in Recurrent Idh1-Mutant High-Grade Glioma

Neonc Technologies Holdings, Inc. Announces Appointment of Nasim Shomali to Board of Directors, Effective July 1, 2026

New minor risk - Market cap size

NeOnc Technologies Holdings, Inc. Receives FDA Written Feedback On NEO212 CMC Development And Capsule-To-Tablet Transition

NeOnc Technologies Holdings, Inc. Announces Board and Committee Changes

NeOnc Technologies Holdings, Inc.(NasdaqGM:NTHI) dropped from Russell 3000E Growth Benchmark

NeOnc Technologies Holdings, Inc. announced that it has received $5.00004 million in funding

NeOnc Technologies Holdings, Inc., Annual General Meeting, Aug 14, 2026

NeOnc Technologies Holdings, Inc. Receives UAE IND Approval For NEO100, Expanding Global Development Ahead Of Anticipated Phase 2 Data Milestone

Neonc Technologies Holdings Receives Abu Dhabi Ind Authorization for Neo212 and Completes Phase 1 Dose-Escalation Study

NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

NeOnc Technologies Holdings, Inc Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

High number of new and inexperienced directors

NeOnc Technologies Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

NeOnc Technologies Holdings, Inc. Appoints David Choi as Chief Accounting Officer

NeOnc Technologies Holdings Reports Phase 1 Dose-Escalation Results and Determines Recommended Phase 2 Dose for Oral Neo212

NeOnc Technologies Holdings, Inc. announced that it expects to receive $15.999998 million in funding

NeOnc Technologies Holdings, Inc. Reports Updated Clinical Results

NeOnc Technologies Holdings, Inc. Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Existing Effective Neo100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies Holdings, Inc. Announces Board Changes, Effective November 12, 2025

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High-Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc Technologies Holding Inc Reports Updated Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100

NeOnc Technologies Holdings, Inc. Announces CEO Changes

NeOnc Technologies Holdings, Inc. Expands NuroMENA Holdings Ltd. Board of Directors

NeOnc Technologies: From Survival Mode To Expansion Mode

Neonc Technologies Holdings, Inc. Appoints David M. Ashley to Its Scientific Advisory Board

NeOnc Technologies Holdings, Inc. Appoints Dr. Alexandra M. Miller to Its Scientific Advisory Board

NeOnc Technologies Holdings, Inc. Appoints Dr. Henry S. Friedman to Scientific Advisory Board

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Holdings, Inc. (NasdaqGM:NTHI) completed the acquisition of Artificial Intelligence, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri.

NeOnc Technologies Holdings, Inc. Announces Resignation of Dr. Ming-Fu Chiang from the Board, Effective August 18, 2025

NeOnc Technologies Holdings, Inc. announced delayed 10-Q filing

NeOnc Technologies Holdings, Inc. Announces the Award of Two Competitive Nih Sttr (Small Business Technology Transfer) Grants Totaling $2.5 Million

NeOnc Technologies Holdings, Inc. Appoints Ishwar K. Puri to Its Board of Directors

NeOnc Technologies Holdings, Inc. announced that it expects to receive $50 million in funding from Quazar Investment

NeOnc Technologies Holdings, Inc. Appoints Josh Neman as Chief Clinical Officer

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of Neo100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Appoints Amir Heshmatpour as President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for Neo212 Brain Cancer Therapy

Neonc Technologies Holdings, Inc. has withdrawn its IPO in the amount of $82.5 million.

No independent directors

CEO